Background-cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy. However, it has never been ascertained whether phosphodiesterase type 5 inhibition exerts an antiremodeling effect in nonischemic heart disease in humans. ; and increased ratio of LV mass to volume, 2.1Ϯ0.5 g/mL) were randomized to receive sildenafil or placebo (100 mg/d). At baseline, the metabolic indices were correlated with torsion, strain, N-terminal pro-B-type natriuretic peptide, vascular endothelial growth factor, monocyte chemotactic protein-1, and blood pressure. After 3 months, sildenafil produced a significant improvement compared with placebo in LV torsion (⌬: sildenafil, Ϫ3.89Ϯ3.11°versus placebo, 2.13Ϯ2.35°; PϽ0.001) and strain (⌬: sildenafil, Ϫ3.30Ϯ1.86% versus placebo, 1.22Ϯ1.84%; PϽ0.001). Sildenafil-induced improvement of LV contraction was accompanied by consistent changes in chamber geometry and performance, with a 6.5Ϯ11% improvement in mass-to-volume ratio over placebo (Pϭ0.021). Monocyte chemotactic protein-1 and transforming growth factor-␤ were the only markers affected by active treatment (⌬monocyte chemotactic protein-1: Ϫ75.30Ϯ159.28 pg/mL, Pϭ0.032; ⌬transforming growth factor-␤: 5.26Ϯ9.67 ng/mL, Pϭ0.009). No changes were found in endothelial function, afterload, or metabolism. Conclusions-The early features of diabetic cardiomyopathy are LV concentric hypertrophy associated with altered myocardial contraction dynamics. Chronic phosphodiesterase type 5 inhibition, at this stage, has an antiremodeling effect, resulting in improved cardiac kinetics and circulating markers. This effect is independent of any other vasodilatory or endothelial effects and is apparently exerted through a direct intramyocardial action. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00692237.
I nhibition of phosphodiesterase type 5 (PDE5) exerts a relaxant effect on the smooth muscle cells of the trabecular structures of the corpora cavernosa, resulting in improved erections. More recently, PDE5 inhibitors have been claimed to offer cardioprotective effects. In vitro and in vivo studies in mice have shown that cGMP and its downstream protein kinase G are signals common to most pathways activated in cardiac hypertrophy. 1 Low levels of PDE5 protein and cGMP-mediated activation of protein kinase G have been found in unstimulated hearts. 2 However, in isolated mouse cardiomyocytes treated with ␤-agonists 2 and in hypertrophic hearts, 3 PDE5 expression is enhanced. 4 These findings suggest that cGMP might block hypertrophic signals and that PDE5 inhibitors might act directly within the cardiomyo-cytes, 3 independently of any concomitant endothelial or vasoactive effects, to regulate myocardial growth and contractility. 5 
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In mouse models, chronic PDE5 inhibition reverts the left ventricular (LV) hypertrophy and fibrosis induced by experimental aortic coarctation, 3, 6 protects against ischemia/reperfusion injury 7 and doxorubicin-induced apoptosis, 8 and prevents cardiac remodeling in hypertrophic cardiomyopathy induced by nitric oxide synthase blockers (N G -nitro-Larginine). 9, 10 However, although there are abundant experimental data in animals, few studies have been conducted in humans. PDE5 protein expression, which is almost undetectable in normal right and left ventricles of the human heart, is strongly upregulated in biopsy samples of the myocardium of hypertrophied chambers. 11 Very recently, a study of patients with heart failure of various etiologies found that PDE5 inhibitors improved LV function and geometry. 12 The effects of PDE5 inhibition have never been explored in humans with nonischemic heart disease. Moreover, the aforementioned studies were not designed to distinguish between an intrinsic cardiac action and indirect secondary changes due to PDE5-induced afterload or endothelial or vasodilatory effects. For this reason, we conducted a prospective randomized controlled clinical trial designed to document intrinsic cardiac changes associated with chronic PDE5 inhibition. The systolic and diastolic dysfunction characteristic of diabetic cardiomyopathy in type 2 diabetes mellitus (T2DM) offered the ideal model. In diabetic cardiomyopathy, chamber remodeling may occur independently of ischemic heart disease, hypertension, or other macrovascular complications. 13 Before chamber dilation and failure, the signs of diabetic cardiomyopathy are a worsening of the cardiac kinetic rate, impaired shortening of cardiac fibers, and an increase in cardiac torsion. [13] [14] [15] These changes can be accurately measured by cardiac magnetic resonance (CMR) imaging, a reproducible, noninvasive method to assess compensatory ventricular remodeling and hypertrophy and quantify kinetic parameters by radiofrequency tagging. 13,16 -18 In the first registered randomized clinical trial designed to investigate the putative antiremodeling effect of PDE5 inhibitors by CMR imaging, we explored the systemic and cardiac effects of the administration of sildenafil, a potent PDE5 inhibitor, at 100 mg/d for 3 months in a large cohort of patients with diabetic cardiomyopathy. spironolactone; prior or current use of PDE5 inhibitors; substance abuse; history of cardiovascular disease, proliferative retinopathy, or autonomic neuropathy; symptoms or signs of ischemic heart disease during cardiac evaluations at enrollment (Figure 1 ; stress ECG and/or 2-dimensional Doppler echocardiography, visit 1; CMR imaging, visit 2); and contraindications to sildenafil use or CMR imaging. Concomitant medications (eg, antihypertensives, statins, oral antidiabetic medications) could not be changed between the 3 months before the study and 1 month after its completion. All subjects gave their written informed consent. The protocol was approved by the hospital ethics committee.
Methods

Subjects
Adverse Events and Compliance
Adverse event reports were collected through monthly follow-up visits and weekly telephone interviews. Adherence was monitored through a monthly pill count.
Study Design
This was a randomized, double-blind (subjects/outcome assessors), placebo-controlled study in T2DM patients. All patients were randomized to receive 100 mg/d sildenafil (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM) or placebo in identical-looking capsules for 3 months. The allocation list was produced with the use of dedicated software by permuted-block randomization with 1:1 allocation with randomly sized blocks. 4 -8 Randomization was not stratified. Allocation was blinded by use of anonymous drug vials with a 4-character alphanumeric code. The sequentially numbered sealed envelopes containing the allocation codes were kept by a pharmacist staff member not involved in the study and were given to the physicians after the informed consent was signed. Codes were broken and unblinded to patients and care providers 3 months after the last patient completion. Blinding was maintained for outcome assessors (ie, the radiologists involved in CMR image analysis and the biologists) until the full statistical analysis had been completed. Patients were monitored monthly for the entire study duration (5 months; Figure 1 ). The study was designed, conducted, and monitored by the study team without industry support and was conducted in collaboration with the departments of experimental medicine and endocrinology; radiology, oncology, and pathology; cardiovascular and respiratory sciences; and internal medicine and medical specialties of Policlinico Umberto I, Sapienza University Hospital of Rome.
Diagnostic Procedures
Symptom-limited stress echocardiography (Philips HDI 5000) was performed (C.D.V.) at visit 1. CMR imaging studies were performed with a 1.5-T clinical magnetic resonance imaging system (Avanto, Siemens, Healthcare Solutions, Erlangen, Germany) with an 8-element phased-array surface receiver coil and ECG triggering. Scout images were used to determine the cardiac axes. Breath-hold balanced, steady state free precession (cine magnetic resonance) sequences were taken with a stack of 10 to 12 short-axis slices covering the whole LV from base to apex for the assessment of ventricular volumes (repetition time/echo time, 5.2/1.2 ms; field of view, 340 -400 mm; matrix, 256ϫ256; slice thickness, 8 mm; interslice gap, 0). A grid generated by saturating orthogonal tags (CMR-tagged imaging; Figure 2A and 2B) was then applied to evaluate myocardial strain and torsion (repetition time/echo time, 4.3/2.4 ms; field of view, 340 -400 mm; matrix, 187ϫ256; flip angle, 15°; slice thickness, 7 mm; band thickness, 7 mm). Breath- hold T1-weighted contrast-enhanced inversion-recovery segmented gradient-echo sequence was performed 10 to 15 minutes after the intravenous injection of contrast agent (0.2 mmol/kg gadolinium-BOPTA; Multihance, Bracco, Milan, Italy) to establish the presence, location, and extent of areas of increased signal intensity (Ͼ5 SD above the normal myocardial signal intensity) due to myocardial regional fibrosis (late gadolinium enhancement imaging). All sequences were performed in vertical and horizontal long-and shortaxis orientations. LV end-diastolic volume (EDV), end-systolic volume, stroke volume, cardiac output, ejection fraction (EF), and LV mass (LVM) were measured on cine magnetic resonance images and indexed to body surface area. Interventricular septum thickness and maximum LV transverse diameter were also measured. CMR analysis was performed independently at visits 2 (time 0) and 5 (Ն3 months) by 2 experienced operators (N.G. and I.C.), who were blinded to the patients' clinical data.
Ventricular Torsion and Strain
Cardiac kinetics, deformation, torsion, recoil, and strain were measured by myocardial tagging. Tags are noninvasive markers that are imprinted on CMR slices, producing signals of varying intensity. 16, 19 Tracking of these signals through the cardiac cycle generates vectors that can be used to quantify movement. Radial tag displacement is used to measure torsion, and deformation of the grid pattern is used to calculate strain (, %). Tags are applied at end-diastole, and images are acquired every 40 ms thereafter, triggered by ECG waves ( Figure 2C to 2F). Tagged images were processed with the use of custom-automated, operator-independent software (Harmonic Phase technology, HARP 1.0, Diagnosoft Inc, Palo Alto, CA).
Customization was limited to tracing of the endocardial and epicardial contours on a single reference cardiac phase for each slice. The program automatically generated and applied 24 points for both contours and propagated them to all cardiac phases. The angle of rotation between the base and apex was calculated as the average rotation of all points in the slice with respect to the LV centroid. The global LV torsion (,°) was calculated as the difference between the counterclockwise (positive) rotation at the apex and clockwise rotation at the base: ϭ apex Ϫ base . The maximum systolic torsion ( max ) was calculated as the largest magnitude of during the cardiac cycle. 19, 20 The directional reversal of systolic torsion during diastole, recoil (untwisting), was described with the use of the equation recoil rate (RR)ϭd ut /dt, defined as the slope of the linear regression of recoil versus time during the first 100 ms after peak torsion (with data from 5 frames). Calculated in this way, the RR was then normalized for peak torsion as RR norm ϭRR/ max (s Ϫ1 ). 20 Further equations describing torsion and recoil are given in Figure I in the online-only Data Supplement.
Flow-mediated vasodilation of the brachial artery was performed (E.G.) at visits 2 and 5 with the use of a high-resolution wideband 7-to 12-MHz linear transducer (Philips HDI 5000) according to a standardized protocol. 21 We monitored 24-hour BP with a portable device at visits 2 and 5, with BP and heart rate measured every 30 minutes.
Laboratory Investigations
Circulating markers were recorded as shown in Figure 1 
Sample Size
The primary efficacy outcome was LV torsion angle (). We arbitrarily specified a clinically significant change of 3°on CMR, according to previous data on LV change 12 months after surgical repair of aortic stenosis (from 16.6Ϯ7.2°to 9.0Ϯ3.4°; PϽ0.05). 17, 22 An overall sample size of 32 subjects (16 for each group) would thus have provided 90% power to detect the specified minimum detectable difference at a 2-sided significance level of 0.01. In determining the sample size, we assumed that 15% of patients would drop out of the study.
Statistical Analysis
Continuous variables are reported as meanϮ1 SD. All variables were tested for normality. Comparative analysis between groups at baseline and after treatment was performed as appropriate by Student t test, 2-way repeated-measures ANOVA, and post hoc comparison (Newman-Keuls test) (with similar results). Statistical analyses were performed with the use of SPSS for Windows, version 18.0 (SPSS, Inc). All statistical comparisons were performed with 2-tailed significance tests, with PՅ0.05 considered statistically significant.
Results
One hundred eight diabetic men were screened ( Figure 1) ; 66 patients were eligible and enrolled (visit 1). Seven were then excluded because of evidence of aneurysm of the ascending aorta (nϭ1) on stress echocardiography and of ischemic heart disease (nϭ6) on the first CMR image. Fifty-nine patients were randomized to receive sildenafil (sildenafil group; nϭ30) or placebo (placebo group; nϭ29) for 3 months (Table  1) . Overall, 54 completed the trial. One man withdrew after 2 months because of portal vein thrombosis, and 4 withdrew for other reasons (claustrophobia, personal reasons, lost at follow-up). There were no drug-related adverse events. The baseline characteristics of the 2 groups, at both randomization and study completion, were well matched (Table 1) . At the baseline (visit 2), all patients exhibited CMR-tagged imaging features compatible with cardiac remodeling induced by nonischemic diabetic cardiomyopathy: increased torsion angle (: 18.4Ϯ4.6°; normal value, Ͻ12°), reduced circumferential strain (: Ϫ12.6Ϯ3.1%; normal value, ϽϪ18%), increased LVM index (119.4Ϯ25.7 g/m 2 ), low-normal EDV index (60.2Ϯ13.9%), and increased ratio of LVM to EDV (LVM/EDV) (2.07Ϯ0.53 g/mL) with normal output (cardiac index: 2.7Ϯ0.6 L/min per square meter; EF: 60.3Ϯ9.3%). All CMR parameters were similar for both groups and were consistent with LV concentric hypertrophy.
The baseline correlation analysis is shown in Table 2 . Torsion was correlated with cardiac mass and geometric remodeling: There was a direct correlation with LVM index and interventricular septum thickness and an inverse correlation with EDV index and ventricular transverse diameter. Strain was also correlated with the cardiac index, whereas neither nor was correlated with EF. Cardiac mass, torsion, and strain were correlated with metabolic impairment (HbA 1c , triglycerides, and body mass index), whereas BP showed no correlation with strain or torsion, confirming that in our cohort CMR changes were secondary to metabolic impairment, independently of hypertension. NT-proBNP was correlated directly with LVM index and EDV index and indirectly with EF but showed no correlation with strain or torsion. MCP1 was correlated with , , metabolic parameters, and TGF-␤ (Figure 3 ). These correlations demonstrate that CMR kinetic parameters provide sensitive estimates of cardiac remodeling before chamber dilation or failure. MCP1 
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was the only chemokine correlated with CMR kinetic contraction parameters. Sildenafil treatment produced a significant improvement in torsion and strain (PϽ0.001), EDV index (Pϭ0.018), concentricity index (LVM/EDV ratio; Pϭ0.021), and cardiac performance with respect to placebo (Table 3) . Within-group posttreatment assessment (Table 3 ) revealed a significant reduction in LV after 3 months of active treatment (⌬sildenafil group: Ϫ3.89Ϯ3.11°, PϽ0.0001) compared with an increase in the placebo group (⌬placebo group: ϩ2.13Ϯ2.35°, PϽ0.0001). This corresponds to a 19.6Ϯ2.5% drop in baseline midwall torsion in treated subjects ( Figure  4) . These results were confirmed transmurally (Table 3) . Intramyocardial strain had also significantly improved in the sildenafil group (⌬sildenafil group: Ϫ3.30Ϯ1.86%, PϽ0.0001) while worsening in the placebo group (⌬placebo group: ϩ1.22Ϯ1.84%, Pϭ0.003) (Figure 4) . Again, these results were confirmed transmurally (Table 3) .
All baseline correlations between cardiac kinetic parameters, metabolic indices, and BP (Table 2 ) had disappeared after treatment in the sildenafil group while remaining in the placebo group (not shown), suggesting that sildenafil has a strong effect on cardiac LV function, independently of other known determinants. Table 3 presents a dynamic assessment of ventricular contraction and relaxation (see also the online-only Data Supplement). There was a significant treatment-related drop in the maximum torsion (T max ; PϽ0.001). No difference was found between the groups for the recoil coefficient (b ut ; Pϭ0.266) or the normalized recoil rate (s Ϫ1 ; Pϭ0.356). Analysis of cardiac morphology showed no changes in cardiac mass, whereas there was a significant increase in EDV index and a significant reduction in ratio of LV mass to volume in the sildenafil group (Ϫ0.17Ϯ0.35 g/mL; Pϭ0.013) compared with the placebo group (ϩ0.02Ϯ0.35 g/mL; Pϭ0.431), confirming an improved LV relaxation and an antiremodeling effect. This corresponds to a 6.5Ϯ11% reduction in concentricity in actively treated subjects.
Because patients with heart failure were excluded, values for cardiac performance were within the normal range for stroke volume, cardiac output, and cardiac index in both groups; for all 3, sildenafil produced an improvement over placebo (Pϭ0.042, Pϭ0.008, Pϭ0.003, respectively). The marginal increase in EF at 3 months in the sildenafil group (ϩ2.77Ϯ4.36%; Pϭ0.002) was not statistically different from that obtained in the placebo group (Pϭ0.793; Table 3 ).
At baseline, there were no differences between the 2 groups with respect to serum biomarkers (Table 4) . Active treatment produced a significant change over placebo only for TGF-␤ (Pϭ0.009) and MCP1 (Pϭ0. 032) levels. Betweengroup analysis showed a significant sildenafil-related reduction in MCP1 (⌬sildenafil group: Ϫ75.30Ϯ159.9 versus BP monitoring revealed an unexpected lowering of systolic and diastolic 24-hour BP in the placebo group only. Endothelial function studies revealed no treatment-related difference in the flow-mediated vasodilation of the brachial artery (data not shown). No differences were found in glycemia, insulin, C-peptide, homeostatic model assessment index, or lipid profile after 3 months of treatment, but HbA 1c dropped in both groups (⌬sildenafil group: Ϫ0.67Ϯ1.09%, Pϭ0.001; ⌬placebo group: Ϫ0.66Ϯ1.37%, Pϭ0.048), and high-density lipoprotein increased over the baseline value in the sildenafil group (0.07Ϯ0.17 mmol/L; Pϭ0.025) ( Table 4) . Betweengroup analysis revealed that there were no treatment-related differences in metabolic parameters.
Discussion
This study characterizes for the first time the early stages of diabetic cardiomyopathy, demonstrating that in this cohort of men with T2DM, chronic PDE5 inhibition exerts an antiremodeling effect by improving the LVM/EDV ratio and CMR-tagged torsion and strain through an endothelialindependent intramyocardial effect, paralleled by changes in inflammatory serum markers.
Features of Diabetic Cardiomyopathy
T2DM currently affects Ͼ180 million people worldwide. Of these, 80% will die of cardiovascular disease. 13, 23 Diabetic cardiomyopathy progresses from early alteration of myocardial interstitium with increased membrane permeability and preserved cell morphology to subsequent enlargement of cardiomyocytes with interstitial and perivascular fibrosis. 13, 24 Geometric ventricular chamber remodeling is initially characterized by low-normal EDV index and normal or only modestly increased LVM. This is associated with systolic/diastolic myocardial dysfunction due to passive stiffness and impaired relaxation. 13, 23 For these reasons, diabetic cardiomyopathy offers a unique model to explore the potential of pharmacological targeting of the pathways leading to cardiac hypertrophy. We further improved the accuracy of the model by excluding patients with silent ischemic heart disease, fibrosis, other vascular disorders, or interfering treatments. Of note is that 6 of the enrolled patients (9%) had CMR signs of previous ischemic disease not otherwise detected on stress echocardiography.
We demonstrated that asymptomatic, "healthy" diabetic patients exhibit CMR features consistent with advanced remodeling. In particular, concentric hypertrophy (increased LVM/EDV ratio, with low-normal EDV index) 25 appears to characterize the early stages of the disease, whereas cardiac performance remains unaffected.
In our study, cardiac changes were correlated with metabolic impairment, indicating that neurohumoral mechanisms triggered by T2DM were responsible for the adaptive changes of the LV (Figure 3) . Having confirmed the dependency on the metabolic disorder, our model of concentric LVH was suitable to assess whether PDE5 inhibition could work as an antiremodeling drug.
The magnitudes of cardiac axial rotation during ventricular contraction (torsion []) and of fiber shortening along the LV long axis (strain []) are the most sensitive indices of systolic function because they are strongly correlated with hypertrophy and fibrosis. 23, 26 Both parameters are precociously af- 
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fected during cardiac remodeling. Similarly, diastolic function can be studied by measuring cardiac recoil rate during ventricular relaxation. In our cohort of asymptomatic, middle-aged T2DM patients, CMR-tagged imaging documented increased torsion angle and decreased strain percentage in comparison with normal subjects. Our baseline CMR data confirm previous echocardiographic studies 27, 28 showing that systolic dysfunction occurs precociously in patients with T1DM 26 and T2DM. 14 We found that early diabetic cardiomyopathy produces an uncoupling between longitudinal strain, which is reduced, and circumferential strain, which is increased. Given the opposite helicoidal orientation of the subepicardial (lefthanded) and subendocardial (right-handed) fibers, global LV torsion is the result of these opposing forces that work to increase shortening. 29 Subepicardial myofibrils, because of their larger radius, produce the dominant force for LV rotation; thus, a dysfunction in the counteracting subendocardial action (eg, due to diffuse fibrosis) could lead to increased torsion and decreased longitudinal shortening. 30 Subendocardial dysfunction due to metabolic impairment could explain the increased torsion paralleling the HbA 1c levels found in our patients.
Torsion and strain were altered in the presence of normal EF and controlled BP. We also demonstrated for the first time a correlation between and MCP1, a serum biomarker of cardiac fibrosis, suggesting a possible pathogenetic role ( Table 2 ).
Antiremodeling Effects of Sildenafil
After 3 months of sildenafil treatment, we observed a significant improvement in strain and torsion. Analyses of the cardiac kinetics showed that peak torsion was significantly reduced, tending toward near-normal values, compared with baseline and the placebo group. PDE5 inhibitor-induced changes in cardiac kinetics improved the cardiac geometry, as reflected by the improved ratio of LVM to volume (an index of LV concentric remodeling) (Figure 4 ). Cardiac performance (EF, cardiac output, and cardiac index) also improved in the sildenafil group. Interestingly, there was a marginal worsening in cardiac dynamics in the placebo group at the end of the study. In this respect, the detrimental progression of the torsion, without changes in recoil, suggests that abnormalities in systolic function might be partly independent of diastolic dysfunction in diabetic cardiomyopathy. 27, 31 The mechanism by which PDE5 inhibitors may exert such effects is under investigation. 32 Increased cGMP through activation of protein kinase G reduces inotropy, exerting a relaxant effect. 5, 33, 34 However, PDE5 overexpression in hypertrophic cardiomyocytes 4 reduces cGMP levels and promotes remodeling. Sildenafil might stop this loop by inhibiting cGMP hydrolysis within the cardiomyocytes. However, its effects could also be secondary to vasodilation or an endothelial-mediated effect.
When exploring afterload, we found no significant changes in 24-hour BP in the active treatment group. This is consistent with our review of randomized clinical trials involving sildenafil that showed no significant effects on BP even after high doses (Table IV in the online-only Data Supplement). A marginal reduction in BP 35, 36 was seen occasionally as an acute effect but diminished with repeated administration. 36 In addition, all of our patients had normal or well-controlled BP, possibly reducing any mild antihypertensive effect. Moreover, the baseline correlation between cardiac kinetics and BP (Table 2 ) was lost after the perturbation induced by PDE5 inhibition. The lack of relationship between the effects produced by sildenafil on torsion and the null effect on BP support the initial hypothesis of a primary cardiac action, independent of any secondary effect on afterload. Having excluded the possibility that improvement in LV dysfunction is afterload dependent, we explored whether it could be the result of an endothelial-dependent action. However, no changes were found in endothelin-1 and vascular endothelial growth factor or in flow-mediated vasodilation.
To study the molecular signals triggered in the cardiomyocytes by PDE5 inhibition, we investigated a large panel of cardiac biomarkers involved in the pathogenesis and progression of diabetic cardiomyopathy. Interestingly, we found that sildenafil lowered TGF-␤ and MCP1 (Figure 4 ), 2 proinflammatory molecules involved in LV remodeling and associated with myocyte growth and fibrosis. 34, 37, 38 It has been found recently that both MCP1 and TGF-␤ are expressed in skeletal muscle cells and hypertrophic cardiomyocytes 39 (also confirmed in our own recent study; A.M. Isidori, MD, PhD, et al, unpublished data, 2012), suggesting that the sildenafilinduced changes in these serum markers could be partly related to a direct cardiac effect. This is consistent with recent animal studies by Kass and colleagues. 37 This theory is further supported by the direct correlation between MCP1 levels and midwall and found at the baseline in our study population. 40 The reduction in these biomarkers may reflect a deactivation of diabetic cardiomyopathy-triggered fibrotic signals following the increase in intracellular cGMP levels, 41 as demonstrated in diabetic nephropathy. 42 The secondary improvement in profibrotic markers and diastolic compliance (EDV index and LVM/EDV ratio) produced by sildenafil suggests that improvement in subendocardial fibrosis could be a mechanism of action.
Finally, we investigated whether metabolic control was involved in the observed cardiac effects and whether it was related to PDE5 inhibitor administration. Although there was a correlation between cardiac kinetics, morphology, and performance at baseline, this had disappeared after 3 months of active treatment. 43 Interestingly, we did not observe any changes in endothelial function. Sildenafil has been found to improve endothelium-dependent vasodilation in some 44, 45 but not all studies. 35,46 -48 Reports of a positive effect on endothelial function mostly involved single-dose trials 35,46 -48 or studies of acute effects. 49 Most of these studies were performed in nondiabetic younger patients or active smokers. 50 A possible explanation for the lack of effect on flowmediated vasodilation is that nitric oxide might make a relatively small contribution to shear stress-induced vasodilation in diabetic patients. In this case, our cohort of patients might have been less sensitive to the endothelium-related effects of sildenafil.
Limitations
In contrast with a recent study, 12 we were unable to detect any changes in LVM index and NTpro-BNP levels. For LVM index, a possible explanation may be the short duration of the treatment (3 versus 12 months). For NTpro-BNP, the lack of change might be due to the inclusion criteria of patients recruited at an early stage of disease, when concentric LV hypertrophy has already developed but not yet evolved to severe eccentric dilation. This is consistent with previous observations showing that when diabetic cardiomyopathy is not accompanied by chamber dilation, there is poor correlation between cardiac kinetics and NTpro-BNP. 27, 31 Another limitation of our study was the lack of a quantitative assessment of diffuse fibrosis (eg, T1 mapping), which would have allowed a better estimation of any treatment-related effect and may have provided evidence for the suggested antifibrotic action of sildenafil. 9 
Conclusions
This study demonstrated that both systolic and diastolic dysfunction are precocious in diabetic cardiomyopathy and associated with a compensatory LV concentric remodeling, whereas cardiac performance at rest remains unaffected. We also showed that morphological and kinetic impairment are related to metabolic status and correlated with circulating proinflammatory chemokines, especially MCP1 and TGF-␤. Dysfunctional LV contraction in diabetic cardiomyopathy can be rapidly improved by chronic PDE5A inhibition through an antiremodeling mechanism independent of vascular, endothelial, or metabolic factors. These findings warrant further studies to discover the intramyocardial mechanisms involved in the antiremodeling effect of sildenafil, as well as long-term outcome studies to quantify the risks and benefits of diabetic cardiomyopathy treatment. Finally, MCP1 could be included as a new marker in the follow-up of patients with diabetic cardiomyopathy, but further mechanistic evidence is necessary to plan future population studies.
